A generic medicines manufacturer exports a batch of cough sy…
A generic medicines manufacturer exports a batch of cough syrup later found to contain diethylene glycol contamination due to a supplier’s mislabelled excipient. Several adverse events are reported locally and internationally. SAHPRA initiates a recall and inspects the manufacturing site. Which of the following regulatory actions is most appropriate as an immediate first step by SAHPRA?
Read DetailsA pharmaceutical company submits an application for registra…
A pharmaceutical company submits an application for registration of a new chemical entity (NCE) in South Africa. The dossier includes only quality (CMC) data, with limited preclinical and no clinical data, based on the assumption that international literature will be sufficient. Which of the following statements is most accurate regarding the data requirements for registration?
Read DetailsA pharmaceutical company is preparing to register a new medi…
A pharmaceutical company is preparing to register a new medicine simultaneously in South Africa, the European Union, and the United States. The scientific data (Modules 2–5) are complete and aligned with ICH CTD requirements. However, the regulatory team proposes submitting the same Module 1 dossier to all three authorities: South African Health Products Regulatory Authority, European Medicines Agency, and U.S. Food and Drug Administration. What is the MOST appropriate regulatory strategy?
Read DetailsA pharmaceutical company is preparing a post-approval variat…
A pharmaceutical company is preparing a post-approval variation for a medicine registered in South Africa. They notice the European Union (EU) Variations Guideline classifies changes into Type IA, IB, and II, while SAHPRA has published a Variations Addendum for local submissions. Which statement best describes the relationship between the EU Variations Guideline and the SAHPRA Variations Addendum?
Read Details